Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3053928 | 0.83 | ALDH1A1 (0.35) | DPP7FDPSALDH1A1MAPTTSHR | |
| SCHEMBL10393853 | 0.79 | F2 (0.31) | — | |
| SCHEMBL4633429 | 0.76 | OPRD1 (0.30) | — | |
| SCHEMBL2672544 | 0.74 | DPP7 (0.38) | DPP7FDPSALDH1A1MAPTTSHR | |
| SCHEMBL11794485 | 0.73 | ALDH1A1 (0.61) | ALDH1A1MAPTTSHRHTTKMT2A | |
| SCHEMBL10714823 | 0.71 | ADH1B (0.32) | FDPSMAPTHTT | |
| SCHEMBL11500064 | 0.70 | ALDH1A1 (0.58) | ALDH1A1MAPTTSHRHTTKMT2A | |
| SCHEMBL6017521 | 0.69 | FDPS (0.33) | FDPS | |
| SCHEMBL6237215 | 0.68 | MAPT (0.40) | DPP7FDPSALDH1A1MAPTTSHR | |
| SCHEMBL4551669 | 0.67 | MAPT (0.34) | DPP7FDPSALDH1A1MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240191238-A1 | BIOMARKERS OF AGING FOR DETECTION AND TREATMENT OF DISORDERS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2024-06-13 | — | — | US | disclosed |
| US-11912998-B2 | Method of treating aging-associated cognitive impairment by reducing CCR3 | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-02-27 | — | — | US | disclosed |
| US-20220213487-A1 | CCR3 MODULATION IN THE TREATMENT OF AGING-ASSOCIATED IMPAIRMENTS, AND COMPOSITIONS FOR PRACTICING THE SAME | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2022-07-07 | — | — | US | disclosed |
| US-11345756-B2 | CCR3 inhibition for ocular angiogenesis and macular degeneration | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2022-05-31 | — | — | US | disclosed |
| US-20220041668-A1 | METHOD OF PROMOTING WOUND HEALING BY INHIBITING CCR3 | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA | 2022-02-10 | — | — | US | disclosed |
| US-11236340-B2 | Method of reducing the effects of aging-associated impairment of neurogenesis comprising modulating c-c chemokine receptor type 3 (CCR3) | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-02-01 | — | — | US | disclosed |
| US-20200399644-A1 | CCR3 MODULATION IN THE TREATMENT OF AGING-ASSOCIATED IMPAIRMENTS, AND COMPOSITIONS FOR PRACTICING THE SAME | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2020-12-24 | — | — | US | disclosed |
| US-10626399-B2 | Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3) | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-04-21 | — | — | US | disclosed |
| US-20200054745-A1 | METHODS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION | LASHKARI KAMERAN (US) | 2020-02-20 | — | — | US | disclosed |
| US-20190276545-A1 | CCR3 Inhibition for Ocular Angiogenesis and Macular Degeneration | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2019-09-12 | — | — | US | disclosed |
| EP-1161240-A1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Du Pont Pharmaceuticals Company (US) | 2001-12-12 | — | — | EP | disclosed |
| EP-1158980-A1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Du Pont Pharmaceuticals Company (US) | 2001-12-05 | — | — | EP | disclosed |
| EP-1156807-A1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Du Pont Pharmaceuticals Company (US) | 2001-11-28 | — | — | EP | disclosed |
| EP-1140086-A1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1140087-A1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000035451-A1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-06-22 | — | — | WO | disclosed |
| WO-2000035449-A1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-06-22 | — | — | WO | disclosed |
| WO-2000035454-A1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-06-22 | — | — | WO | disclosed |
| WO-2000035452-A1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-06-22 | — | — | WO | disclosed |
| WO-2000035453-A1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-06-22 | — | — | WO | disclosed |